A side-by-side comparison of the leading repeal-and-replace proposals.
Oliver Wyman Health
2 min read
Table of Contents
The below infographic shares a side-by-side comparison of the leading repeal-and-replace proposals.
What President-Elect Trump’s Unexpected Win Means for BioPharma
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
True Value Chain Pharma Disruption is (Finally) Here to Stay
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
New Survey: CSR Uncertainty Looms Large Over Payers
Survey responses confirm that CSR defunding would have a significant impact on 2018 rates and payers’ continued participation in the ACA exchanges.
Four Key Considerations for the ACA in 2018
What lies ahead for insurers as the ACA 2018 open enrollment period approaches.